share_log

Goldman Sachs Maintains Neutral on Nautilus Biotechnology, Lowers Price Target to $2

Benzinga Real-time News ·  Aug 3, 2022 09:20

Goldman Sachs analyst Matthew Sykes maintains Nautilus Biotechnology (NASDAQ:NAUT) with a Neutral and lowers the price target from $4 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment